The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: A pilot trial from the GETH and GELLC (CLL4 trial)

1. Montesinos, P.
2. Cabrero, M.
3. Valcárcel, D.
4. Rovira, M.
5. García-Marco, J.A.
6. Loscertales, J.
7. Moreno, C.
8. Duarte, R.
9. Terol, M.J.
10. Villamor, N.
11. Abrisqueta, P.
12. Caballero, D.
13. Sanz, J.
14. Delgado, J.